Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: vepdegestrant for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102 for the treatment of patients with neurodegenerative disorders, and ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas.
In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC® androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.
#TeamArvinas is made up of approximately 450 passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.
For more information, please visit www.arvinas.com.
Position Summary
The Director, Medical Writer is responsible for development and management of medical writing deliverables that support the clinical regulatory writing portfolio and is capable of working independently to achieve goals. The Director, Medical Writer is responsible for leading a team and/or Therapeutic Area, managing all documentation, ensuring consistency, assigning resources, and managing/mentoring writing resources as required in order to execute on the writing deliverables across the clinical and regulatory portfolio.
Serving as a link among key functions, the Director, Medical Writer ensures that critical information is communicated with clarity, precision, and accessibility. This individual works cross-functionally to prepare and update documents, including clinical protocols, annual reports, Investigator Brochures, abstracts, clinical study reports, manuscripts, and regulatory authority briefing materials, to support product development. The Director, Medical Writer will help develop processes, manage and maintain processes, assist in development of templates, and train of new staff. This is a unique opportunity to influence Medical Writing best practices and help create an efficient and forward-thinking Medical Writing team.
This position reports to the Senior Director of Medical Writing, Clinical Development and can be remote, hybrid, or located at our headquarters in New Haven, CT.
Principal Responsibilities
Key responsibilities of this role include, but are not limited to:
Qualifications
Education
#LI-Remote
Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com
Ascendis Pharma
MMS
Lifelancer
CallTek
UnitedHealth Group